Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)
Close on Nov 16, 2026Market cap $303.43MP/E –Yield –
Autolus Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Autolus Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 15.7%. For fiscal 2025 it was -27.8%, against -12.5% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -27.8% | −15.3 |
| FY2024 | Dec 31, 2024 | -12.5% | −112.5 |
| FY2023 | Dec 31, 2023 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | 55.2% | +72.0 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | 6.3% | +106.1 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -4.3% | +39161.2 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -35.1% | −135.1 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -16.8% | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -99.9% | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -39165.5% | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | 100.0% | – |
See a number that looks wrong?